Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.
Angle Plc (ANPCY) provides cutting-edge liquid biopsy solutions for cancer diagnostics and research. This news hub delivers official updates on clinical trial progress, regulatory milestones, and strategic partnerships shaping precision oncology.
Access verified announcements about the Parsortix system deployments, novel assay developments, and collaborations with pharmaceutical leaders. Investors and researchers will find timely reports on FDA submissions, peer-reviewed study publications, and innovations in circulating tumor cell (CTC) analysis.
Key updates include product launch details, intellectual property expansions, and clinical service offerings supporting drug development. All content undergoes strict verification to ensure accuracy in reporting financial and operational developments.
Bookmark this page for consolidated access to Angle Plc's latest advancements in non-invasive cancer diagnostics and genomic analysis technologies.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced new share option grants under its Long-Term Incentive Plan (LTIP) and staff share option plans. The company approved 12 million LTIP Options for executive directors and up to 13.8 million Staff Share Options.
The allocation considers that no bonuses were awarded for three consecutive years to conserve cash. The Staff Share Options are priced at 10.00 pence per share, 2.6% above the closing price of 9.75 pence on March 20, 2025. Following these grants, ANGLE will have outstanding options over 51,369,480 Ordinary Shares, representing 13.7% of issued capital, within the approved 16% limit.
The LTIP Options include a three-year performance period plus a two-year holding period, with performance conditions linked to share price CAGR above the June 2024 funding round price of 15.00 pence per share.
ANGLE plc (ANPCY) has announced successful completion of key development projects with AstraZeneca and Eisai. The company has developed two assays for AstraZeneca: a prostate cancer androgen receptor (AR) assay and a multi-cancer DDR micronuclei assay for DNA damage detection in CTCs.
The AR therapeutic market is projected to reach $9.2 billion by 2033, with over 46,000 patients in 181 clinical studies. The DDR therapeutic market, valued at $8.2 billion in 2024, is expected to grow to $30.3 billion in the next decade.
Additionally, ANGLE's Parsortix-based HER2 assay demonstrated successful results in Eisai's Phase 2 pilot study for breast cancer patients, showing the ability to measure HER2 status changes over time. The HER2 therapeutic market, valued at $9.4 billion in 2023, is projected to reach $13.2 billion by 2030.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced successful results from its dual analysis of circulating tumor DNA (ctDNA) and CTC-DNA using Illumina's technology platform. The study, conducted on 27 lung cancer patients, demonstrated that 100% of untreated patients and 90% of treated patients had cancer mutations identified exclusively in CTC-DNA, not found in ctDNA from the same blood sample.
The research utilized Illumina's customized 79-gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. The dual analysis approach found twice as many mutations compared to single-analyte testing, potentially providing more comprehensive biomarkers for treatment guidance.
Following these positive results, ANGLE has been invited to present their findings at an EACR-Illumina webinar on February 6, 2025. This marks the first joint marketing initiative between ANGLE and Illumina, whose NGS systems are installed across more than 9,500 customers in 155 countries.
ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.
The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.
The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), a liquid biopsy company, released its trading update for FY2024. Revenue increased 31% to £2.9 million (from £2.2 million in FY23). The company maintains a strong cash position of £10.4 million as of December 31, 2024, with expected R&D tax credits of £1.4 million in Q1 2025 and £0.8 million in Q3 2025, totaling available cash resources of £12.6 million.
The company's annual loss decreased 30% to approximately £14 million (from £20.1 million in FY23), aligning with guidance. Following strategic focus on pharma services and cost reduction, current cash reserves provide runway into 2026. The company expects higher revenue growth in 2025 compared to 2024, with potential for significant increase over time, supported by progressing pharma contracts and new opportunities.
ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.
The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.
ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.
ANGLE plc presented new data at the AACR Special Conference regarding their development of a Parsortix-based HER2 assay kit in collaboration with BioView. The study, involving 43 metastatic breast cancer patients, showcased a scoring system for HER2 expression in circulating tumor cells (CTCs). The research demonstrated that some initially HER2-negative patients became HER2-positive over time, as detected through CTC analysis. This blood-based test could enable identification of patients who might benefit from HER2-targeted therapies, particularly important since approximately 80% of breast cancer patients are initially categorized as HER2-negative, but their status can change over time.
ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.
The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.
ANGLE plc announced research findings on dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. The study, conducted by the National and Kapodistrian University of Athens, used the Parsortix system to analyze 30 NSCLC patients treated with osimertinib. The research demonstrated that dual analysis of CTC-DNA and ctDNA provides complementary information, enabling better identification of resistance mutations and DNA methylation at disease progression. The study also revealed druggable molecular markers that could inform combined targeted treatment approaches, supporting ANGLE's pharma services strategy.
